CARA THERAPEUTICS INC

Cara Therapeutics Reports Second Quarter 2021 Financial Results

09 Aug 2021 15:01:00 By Nasdaq GlobeNewswire

Cara Therapeutics to Announce Second Quarter 2021 Financial Results on August 9, 2021

02 Aug 2021 15:01:00 By Nasdaq GlobeNewswire

Cara Therapeutics to Present at the Jefferies Healthcare Conference

25 May 2021 06:00:00 By Nasdaq GlobeNewswire

Cara Therapeutics Reports First Quarter 2021 Financial Results

10 May 2021 15:01:00 By Nasdaq GlobeNewswire

Cara Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference

06 May 2021 15:01:01 By Nasdaq GlobeNewswire

Cara Therapeutics to Announce First Quarter 2021 Financial Results on May 10, 2021

03 May 2021 15:01:00 By Nasdaq GlobeNewswire

Cara Therapeutics to Present at the 20th Annual Needham Healthcare Conference

07 Apr 2021 15:01:00 By Nasdaq GlobeNewswire

Cara Therapeutics to Host Virtual Research and Development Event on April 7, 2021

31 Mar 2021 06:00:00 By Nasdaq GlobeNewswire

VFMCRP and Cara Therapeutics announce European Medicines Agency has accepted to review the Marketing Authorization Application for difelikefalin

30 Mar 2021 00:00:00 By Nasdaq GlobeNewswire

Cara Therapeutics and Vifor Pharma announce U.S. FDA acceptance and Priority Review of NDA for KORSUVA™* injection in hemodialysis patients with moderate-to-severe pruritus

08 Mar 2021 00:00:00 By Nasdaq GlobeNewswire

Cara Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results

25 Feb 2021 15:01:01 By Nasdaq GlobeNewswire

Cara Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021

18 Feb 2021 15:01:00 By Nasdaq GlobeNewswire

Cara Initiates Phase 2 Trial of Oral KORSUVA™ for the Treatment of Pruritus in Patients with Notalgia Paresthetica

11 Jan 2021 06:00:01 By Nasdaq GlobeNewswire

Cara Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

06 Jan 2021 06:00:00 By Nasdaq GlobeNewswire